Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals "GAMES-RP"

Active, not recruiting

Phase 2 Results N/A

Summary of Purpose

This is a randomized, multi-center, prospective, double blind study. The primary objective is to demonstrate the efficacy of RP-1127 compared to placebo in subjects with a severe anterior circulation ischemic stroke who are likely to develop malignant edema. This objective will be addressed by comparing the proportion of RP-1127 treated patients and placebo treated patients with a Day 90 modified Rankin Scale...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 31 May 2015.

1 May 2013 14 Feb 2013 1 Aug 2015 1 Apr 2016 1 May 2015 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Prevention
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • W. Taylor Kimberly, MD, PhD

  • Kevin N Sheth, MD